Dr. Choi's research focuses on the role of RNA-binding proteins in the regulation of alternative splicing and how mutations in these factors contribute to cancer. He uses a combination of genetically-engineered models and high-throughput approaches to better understand how alternative splicing influences cellular function and to identify potential opportunities for therapeutic intervention.
It is scary to learn your child has neuroblastoma, a tumor of the peripheral nervous system that is the most common cancer in infants. It is scarier still when you get test results that show your child is in the half of neuroblastoma patients whose cancer is very aggressive and high-risk.
The Hogarty Laboratory studies the childhood tumor neuroblastoma. This enigmatic tumor is responsible for 15% of all childhood cancer deaths despite the use of highly intensive therapies, and survivors often suffer lifelong toxicities from their treatments. New approaches are needed to improve outcomes, and the lab seeks to understand the biology driving aggressive tumor behavior, and identify unique tumor-specific vulnerabilities.
The Mossé Laboratory studies the role of the anaplastic lymphoma kinase (ALK) oncogene in the initiation and progression of neuroblastoma, with a focus on developing innovative therapeutic strategies for patients with this often lethal disease.
Research in the Cole Lab focuses on identifying therapeutic vulnerabilities within molecularly defined subsets of pediatric central nervous system malignancies. The long-term goal of the lab is to identify effective therapies and improve the cure rate of children with malignant brain tumors.